Indian pharma industry needs to adopt digital technologies, says EY report

India is the largest provider of generic drugs globally, fulfilling about 40 per cent of the generics demand in the US and roughly 25 per cent of all medicines in UK

The average drug manufacturing utilisation rate in India is roughly 75 per cent across both active pharmaceutical ingredients (APIs) and formulation production facilities. This means 25 per cent of the capacity goes unused due to the inherent variability in processes, according to global advisory services firm EY.

"The Indian pharma industry boasts of a strong network of 10,500 manufacturing sites. However, most of these plants use traditional batch manufacturing processes resulting in longer production times and increased chances of error due to high human intervention. Inefficient manufacturing costs the industry millions of dollars every year according to an industry bench